Abstract：Objective To analyze the clinicopathological features and survival of patients with metastatic triple-negative breast cancer (TNBC) and the value of locoregional treatment for metastatic TNBC. Methods A retrospective analysis was performed on the clinical features and treatment outcomes of 220 patients with metastatic TNBC admitted from 1998 to 2013. Of them, 206 patients with stage Ⅰ—Ⅲ disease developed metastasis disease after treatment (186 patients undergoing modified radical mastectomy, 14 patients undergoing breast-conserving surgery plus radiotherapy, 5 patients undergoing breast-conserving surgery alone, and one patient not undergoing surgery;196 patients receiving chemotherapy, and 88 patients receiving locoregional radiotherapy after modified radical mastectomy), and 14 patients presented stage Ⅳ disease (8 patients undergoing modified radical mastectomy, one patient undergoing segmental mastectomy, and 5 patients not undergoing surgery). Overall survival (OS) and progression-free survival were calculated by the Kaplan-Meier method;the log-rank test and univariate prognostic analysis were used to assess treatment outcomes. Results The most common metastatic sites were the lung followed by bones. Of all patients, 182(82.7%) developed visceral organs metastasis. Sixty-three (28.6%) developed metastasis to a single organ, whereas 182 (69.5%) withmultiple metastatic disease and 4 patients were unclear.Most patients developed distant metastasis within 3 years after the initial diagnosis of TNBC, and only 6.4% of all patients developed distant metastasis over 5 years later. With a median follow-up of 22 months, the 5-year OS was 25.0%, and the median survival time was 21 months.The 5-year OS of patients with single metastasis was 38.2%, compared with 17.5% for those with multiple metastases (P=0.005). The 5-year OS of patients with visceral organ metastasis was 20.3%,compared with 56.2%for those with metastasis inbones (P=0.049). For 63 patients with singlemetastasis, those receiving locoregional treatment with radiotherapy or surgery had a significantly increasedOS compared with those receiving no locoregional treatment (48% vs 29%, P=0.006). Conclusions Patients with metastatic TNBC usually present with visceral metastasis. Patients with single metastasis have a better outcomes than those with multiple metastases. Patients with metastasis in bones have a better autcomes than those with visceral organs involved. Locoregional treatment significantly improved the overall survival in patients with single metastasis.
Wu Tao,Wang Shulian,Jin Jing et al. Clinicopathological features and treatment outcomes for patients with metastatic triple-negative breast cancer[J]. Chinese Journal of Radiation Oncology, 2014, 23(3): 177-180.
[1] Mosconi P, Colozza M, De Laurentiis M, et al. Survival, quality of life and breast cancer[J]. Ann Oncol,2001;12 Suppl 3:S15-19. [2] Kondziolka D, Kano H, Harrison GL, et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer[J]. J Neurosurg,2011,114:792-800. [3] Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer[J]. Breast Cancer Res Treat,2009,115:423-428. [4] Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in 1,038 women with metastatic breast cancer[J]. Ann Oncol,2008,19:2012-2019. [5] Geiger S, Cnossen JA, Horster S, et al. Long-term follow-up of patients with metastatic breast cancer:results of a retrospective, single-center analysis from 2000 to 2005[J]. Anticancer Drugs,2011,22:933-939. [6] Ryberg M, Nielsen D, Osterlind K, et al. Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy[J]. Ann Oncol,2001,12:81-87. [7] Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes[J]. J Clin Oncol,2010,28:3271-3277. [8] Luck AA, Evans AJ, Green AR, et al. The influence of basal phenotype on the metastatic pattern of breast cancer[J].Clin Oncol (R Coll Radiol),2008,20:40-45. [9] Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast carcinoma:importance of prognostic markers of the primary tumor[J]. Cancer,2003,97:545-553. [10] Khanfir A, Lahiani F, Bouzguenda R, et al. Prognostic factors and survival in metastatic breast cancer:a single institution experience[J]. Rep Pract Oncol Radiother,2013,18:127-132. [11] Sherry MM, Greco FA, Johnson DH, et al. Metastatic breast cancer confined to the skeletal system. An indolent disease[J]. Am J Med,1986,81:381-386. [12] Briasoulis E, Karavasilis V, Kostadima L, et al. Metastatic breast carcinoma confined to bone:portrait of a clinical entity[J]. Cancer,2004,101:1524-1528. [13] Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone[J].Cancer Cell,2003,3:537-549. [14] Fidler IJ. The pathogenesis of cancer metastasis:the′seed and soil′ hypothesis revisited[J]. Nat Rev Cancer,2003,3:453-458. [15] Goodison S, Kawai K, Hihara J, et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein[J]. Clin Cancer Res,2003, 9:3808-3814. [16] Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis[J]. J Clin Oncol,2006,24:2743-2749. [17] Nguyen DH, Truong PT, Alexander C, et al. Can locoregional treatment of the primary tumor improve outcomes for women with stage ⅠV breast cancer at diagnosis[J]? Int J Radiat Oncol Biol Phys,2012,84:39-45. [18] Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer[J]? Surgery,2002,132:620-626. [19] Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer[J]. N Engl J Med,2004,351:781-791. [20] Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells:a novel prognostic factor for newly diagnosed metastatic breast cancer[J]. J Clin Oncol,2005,23:1420-1430. [21] Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer,2007,7:134-144. [22] Metzger-Filho O, Sun Z, Viale G, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease:results from International Breast Cancer Study Group Trials VⅢ and IX[J]. J Clin Oncol,2013,31:3083-3090.
2014, Vol. 23 
